These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29190085)

  • 41. Ligand-guided receptor optimization.
    Katritch V; Rueda M; Abagyan R
    Methods Mol Biol; 2012; 857():189-205. PubMed ID: 22323222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigation of MM-PBSA rescoring of docking poses.
    Thompson DC; Humblet C; Joseph-McCarthy D
    J Chem Inf Model; 2008 May; 48(5):1081-91. PubMed ID: 18465849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Large scale free energy calculations for blind predictions of protein-ligand binding: the D3R Grand Challenge 2015.
    Deng N; Flynn WF; Xia J; Vijayan RS; Zhang B; He P; Mentes A; Gallicchio E; Levy RM
    J Comput Aided Mol Des; 2016 Sep; 30(9):743-751. PubMed ID: 27562018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Studies of protein-ligand interactions by NMR.
    Craik DJ; Wilce JA
    Methods Mol Biol; 1997; 60():195-232. PubMed ID: 9276249
    [No Abstract]   [Full Text] [Related]  

  • 45. Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.
    Duffy BC; Liu S; Martin GS; Wang R; Hsia MM; Zhao H; Guo C; Ellis M; Quinn JF; Kharenko OA; Norek K; Gesner EM; Young PR; McLure KG; Wagner GS; Lakshminarasimhan D; White A; Suto RK; Hansen HC; Kitchen DB
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2818-23. PubMed ID: 26022843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of multiple binding modes in ligand-protein docking.
    Källblad P; Mancera RL; Todorov NP
    J Med Chem; 2004 Jun; 47(13):3334-7. PubMed ID: 15189030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NMR-guided molecular docking of a protein-peptide complex based on ant colony optimization.
    Korb O; Möller HM; Exner TE
    ChemMedChem; 2010 Jul; 5(7):1001-6. PubMed ID: 20486157
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How much NMR data is required to determine a protein-ligand complex structure?
    Schieborr U; Vogtherr M; Elshorst B; Betz M; Grimme S; Pescatore B; Langer T; Saxena K; Schwalbe H
    Chembiochem; 2005 Oct; 6(10):1891-8. PubMed ID: 16013076
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Testing inhomogeneous solvation theory in structure-based ligand discovery.
    Balius TE; Fischer M; Stein RM; Adler TB; Nguyen CN; Cruz A; Gilson MK; Kurtzman T; Shoichet BK
    Proc Natl Acad Sci U S A; 2017 Aug; 114(33):E6839-E6846. PubMed ID: 28760952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protein-ligand docking guided by ligand pharmacophore-mapping experiment by NMR.
    Fukunishi Y; Mizukoshi Y; Takeuchi K; Shimada I; Takahashi H; Nakamura H
    J Mol Graph Model; 2011 Nov; 31():20-7. PubMed ID: 21940186
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modeling complexes of modeled proteins.
    Anishchenko I; Kundrotas PJ; Vakser IA
    Proteins; 2017 Mar; 85(3):470-478. PubMed ID: 27701777
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FlexE: efficient molecular docking considering protein structure variations.
    Claussen H; Buning C; Rarey M; Lengauer T
    J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structure-based development of target-specific compound libraries.
    Orry AJ; Abagyan RA; Cavasotto CN
    Drug Discov Today; 2006 Mar; 11(5-6):261-6. PubMed ID: 16580603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Essential considerations for using protein-ligand structures in drug discovery.
    Warren GL; Do TD; Kelley BP; Nicholls A; Warren SD
    Drug Discov Today; 2012 Dec; 17(23-24):1270-81. PubMed ID: 22728777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Post-docking optimization and analysis of protein-ligand interactions of estrogen receptor alpha using AMMOS software.
    Pencheva T; Jereva D; Miteva MA; Pajeva I
    Curr Comput Aided Drug Des; 2013 Mar; 9(1):83-94. PubMed ID: 23106778
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural quality of unrefined models in protein docking.
    Anishchenko I; Kundrotas PJ; Vakser IA
    Proteins; 2017 Jan; 85(1):39-45. PubMed ID: 27756103
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDS: flexible ligand and receptor docking with a continuum solvent model and soft-core energy function.
    Taylor RD; Jewsbury PJ; Essex JW
    J Comput Chem; 2003 Oct; 24(13):1637-56. PubMed ID: 12926007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: the prediction accuracy of sampling power and scoring power.
    Wang Z; Sun H; Yao X; Li D; Xu L; Li Y; Tian S; Hou T
    Phys Chem Chem Phys; 2016 May; 18(18):12964-75. PubMed ID: 27108770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ligand-target interactions: what can we learn from NMR?
    Carlomagno T
    Annu Rev Biophys Biomol Struct; 2005; 34():245-66. PubMed ID: 15869390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure-guided fragment screening for lead discovery.
    Verdonk ML; Hartshorn MJ
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):404-10. PubMed ID: 15338949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.